ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(21 sites)
United States
Honor Health Research Institute, Scottsdale, Arizona City of Hope National Medical Center, Duarte, California City of Hope Orange County, Irvine, California Florida cancer specialist/Sarah Cannon Research Institute, Sarasota, Florida The Cleveland Clinic, Cleveland, Ohio MD Anderson Cancer Center, Houston, Texas Fred Hutchinson Cancer Center, Seattle, Washington China
Fujian Cancer Hospital, Fuzhou, Fujian SunYat-Sen University Cancer Center, Guangzhou, Guangdong Hong Kong Humanity & Health Clinical Trial Center, Hong Kong, Hong Kong Prince of Wales Hospital, Hong Kong, Hong Kong South Korea
Dong -A University Hospital, Seogu, Busan Gwangyeogsi CHA Bundang Medical Center, CHA university, Seongnam, Gyeonggido The Catholic University of Korea Street. Vincent Hospital, Suwon, Gyeonggido Chungbuk National University Hospital, Cheongju-si, North Chungcheong Samsung Medical Center, Seoul, Seoul Teugbyeolsi Keimyung University Dongsan Hospital, Daegu Seoul National University Hospital, Seoul KangBuk Samsung Hospital, Seoul Asan Medical Center, Seoul Severance Hospital Yonsei University Health System, Seoul Last updated January 2026